Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $25.00.

BCYC has been the subject of a number of research reports. JMP Securities dropped their price objective on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a research note on Friday, May 2nd. B. Riley lowered their target price on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Needham & Company LLC reissued a "buy" rating and set a $29.00 target price on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Royal Bank Of Canada lowered their target price on Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Barclays lowered their target price on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st.

Institutional Trading of Bicycle Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC raised its stake in Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after acquiring an additional 2,345 shares during the last quarter. GAMMA Investing LLC raised its stake in Bicycle Therapeutics by 879.5% during the 1st quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock valued at $76,000 after acquiring an additional 8,065 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Bicycle Therapeutics by 90.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after purchasing an additional 6,057 shares during the period. Cerity Partners LLC acquired a new position in Bicycle Therapeutics during the 1st quarter worth approximately $113,000. Finally, Portland Investment Counsel Inc. acquired a new position in Bicycle Therapeutics during the 1st quarter worth approximately $127,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Stock Down 0.2%

BCYC stock opened at $7.43 on Friday. The business has a fifty day moving average of $8.09 and a two-hundred day moving average of $10.17. The stock has a market cap of $514.18 million, a price-to-earnings ratio of -2.36 and a beta of 1.41. Bicycle Therapeutics has a 52-week low of $6.10 and a 52-week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 25.54% and a negative net margin of 790.07%. The business had revenue of $9.98 million for the quarter, compared to analyst estimates of $8.67 million. As a group, sell-side analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.